Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Session Evaluation

POLICY

EARLY CAREER INVOLVEMENT

125 - POST-VACCINE MYOCARDITIS AND PERICARDITIS: UPDATE FROM THE CCS MYCOVACC SURVEILLANCE STUDY

Thursday, October 24, 2024
9:45 AM - 10:45 AM PT
Room: 212-213
Early Career Involvement
Workshop Description: Myocarditis and pericarditis after mRNA COVID-19 vaccination are rare, and most cases are mild and self-limiting; however, the longer-term health and functional implications of the acute myocardial and pericardial injury remain uncertain. This knowledge gap can impact confidence in vaccines, particularly for young adults and children. This session will update the Canadian cardiovascular community on post-vaccine myocarditis and pericarditis. We will review current guidance as well as Canadian Cardiovascular Society (CCS) knowledge translation tools about the management of vaccine-associated myocarditis and pericarditis using an illustrative clinical vignette. The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) will be described including partner sites, participant recruitment, and early data from the main study and extension studies. Participants will have an opportunity to explore ways of further engaging in the project.

Interactive and Engagement Activities Description: We will have 4 to 5 speakers covering each topic for a total of 30 minutes, followed by a panel discussion. At least 25% of the session will be dedicated to Q&A, audience interaction, and opportunities for participants to explore ways of further engaging in the project.

Learning Objectives:

At the end of this session participants will be able to:
  • identify key knowledge gaps in the management and follow-up of patients with post- myocarditis and pericarditis;
  • describe the scope and breadth of the MYCOVACC surveillance study and early study results; and
  • apply current clinical guidance and knowledge translation tools in the management and follow-up of patients with post-vaccine myocarditis and pericarditis.
Disclosure(s):
Michael A. McDonald, MD: Abbott: Consultant/Advisory Board (Terminated, May 23, 2024)
Carolyn Pullen, BNSc, RN, PhD: No financial relationships to disclose
Nathaniel M. Hawkins, MBChB MD MPH FESC: AstraZenica: Consultancy (Ongoing), Randomized Clinical Trial (Ongoing), Speakers' Bureau (Ongoing); NovoNordisk: Advisory Board (Ongoing)
Tahir S. Kafil, MD FRCPC: No financial relationships to disclose
Michael Khoury, MD, FRCPC: Ultragenyx: Advisory board for familial hypercholesterolemia (Ongoing)
Adriana C. Luk, MD, MSc: No financial relationships to disclose
James A. White, MD: Bristol Meyers Squibb: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Cohesic Inc: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Pfizer Inc: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)